Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma · Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC) · Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) · Small Cell Lung Cancer (SCLC) · Gastroenteropancreatic NEC (GEP NEC) · NEC of the Bladder · Other DLL3 Expressing epNEC
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 138 (planned)
- Started
- May 18, 2026
- Main results expected
- Sep 2028
- Fully finished
- Sep 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279
Measured over: until 5 years after last dose
To assess dose modifications of [212Pb]Pb-DOTAM-MAM279
Measured over: until 5 years after last dose
To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs
Measured over: Phase 1, from start of treatment to end of first cycle (day 1 - 28)
To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
Measured over: Phase 2a only; 12 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07278479 · record last updated 2026-10-21 · checked 2026-11-09 15:47 UTC